Management of HIV Patients with Detected KSHV

Introduction to KSHV Detection and Management

The detection of KSHV does not automatically indicate active disease requiring treatment, and the most critical immediate action is to optimize antiretroviral therapy (ART) and conduct a thorough clinical assessment for Kaposi sarcoma lesions, according to the National Comprehensive Cancer Network 1, 2
KSHV (HHV-8) detection alone does not equal Kaposi sarcoma disease—the virus is present in 38% of ART-naïve HIV patients, but most remain asymptomatic, as reported by the Journal of the National Comprehensive Cancer Network 2
KSHV is universally associated with KS (95-98% of KS cases are seropositive), but immunosuppression is the critical cofactor for disease development, according to the Journal of the National Comprehensive Cancer Network 2

A complete skin examination documenting any violaceous, red, or brown patches, plaques, or nodules (photograph lesions if present) is essential for diagnosis, as recommended by the National Comprehensive Cancer Network and Praxis Medical Insights 1, 2
An oral cavity examination for palatal, gingival, or tongue lesions is also crucial, according to the National Comprehensive Cancer Network and Praxis Medical Insights 1, 2
Lymph node examination with documentation of any lymphadenopathy is necessary, as reported by the National Comprehensive Cancer Network and Praxis Medical Insights 1, 2
Assessment for edema, particularly lower extremity or facial, is important, according to the National Comprehensive Cancer Network and Praxis Medical Insights 1, 2

If no clinical evidence of Kaposi sarcoma is found, initiate or optimize ART immediately—potent antiretroviral combinations that suppress HIV replication reduce KS frequency, as recommended by the Annals of Internal Medicine and MMWR Recommendations and Reports 3, 4, 5
If asymptomatic/cosmetically acceptable KS lesions are found, ART alone is the preferred initial approach—remissions or stable disease may occur with optimization of immune function and viral suppression, according to Praxis Medical Insights 1
If symptomatic or cosmetically unacceptable limited disease is present, ART plus minimally invasive local therapy is recommended, as reported by Praxis Medical Insights 1
If advanced disease (extensive cutaneous, oral, visceral, or nodal) is found, ART plus systemic chemotherapy is necessary, according to Praxis Medical Insights 1

Liposomal doxorubicin is the first-line systemic therapy for advanced disease, as recommended by Praxis Medical Insights 1, 6
Paclitaxel is an equivalent alternative first-line option (statistically equivalent response rates, progression-free survival, and 2-year survival), according to Praxis Medical Insights 6
Ensure neutrophil count ≥1,000 cells/mm³ before initiating paclitaxel in immunosuppressed patients, as reported by Praxis Medical Insights 6

KS-IRIS occurs in 6-39% of patients within 3-6 months of ART initiation, according to Praxis Medical Insights 1, 7
Presents as paradoxical worsening of lesions despite immune recovery, as reported by Praxis Medical Insights 7
Continue ART in most cases unless life-threatening complications develop, according to Praxis Medical Insights 7

Absolutely avoid glucocorticoids in patients with active or prior KS due to potential for significant flares, as recommended by Praxis Medical Insights 1
Avoid rituximab and cyclosporine (suppress B- and T-cell function, associated with KS flares), according to Praxis Medical Insights 1

KSHV is not eradicated with treatment—ongoing risk of recurrence persists even after complete remission, as reported by Praxis Medical Insights 1
Disease can recur even with normal CD4+ counts and undetectable viral loads, according to the Journal of the National Comprehensive Cancer Network and Praxis Medical Insights 8, 1
Regular surveillance includes: complete skin/oral exams, CD4+ count, HIV viral load, and ART compliance assessment, as recommended by the Journal of the National Comprehensive Cancer Network and Praxis Medical Insights 8, 1

Referral to HIV specialist is essential for ART optimization, according to the Journal of the National Comprehensive Cancer Network and Praxis Medical Insights 2, 1
Consider infectious disease consultation to exclude KS mimics (bacillary angiomatosis, blastomycosis, cryptococcosis) if lesions are present, as reported by the Journal of the National Comprehensive Cancer Network 2
Oncology referral if systemic therapy is needed, according to the Journal of the National Comprehensive Cancer Network and Praxis Medical Insights 2, 1